South African self-screening medical testing provider, UDoTest™, has been accepted into a six month incubator programme led by Launchpad Digital Health, an incubator with innovative programmes for start-ups wanting to pressure test their businesses in the US, following their successful involvement in the Discovery Entrepreneurs Medical Technology Programme.

UDoTest was founded by Allison Martin, who is also the CEO of the company, and offers accurate self-screening pathology tests, currently in the disease areas of HPV, STD, Colon and Gluten Intolerance detection.

UdoTest was one of 13 leading South African medical technology entrepreneurs chosen by Discovery to partake in the inaugural Discovery Entrepreneurs Medical Technology Programme, from November 27 to December 3 2016.

As part of the programme, the chosen health and wellness enterprises and entrepreneurs embarked on a week long, fully funded educational business visit to Silicon Valley in the US where the latest in global technology-driven innovation was explored.

The startups also received business mentorship going forward, access to company development and procurement support, as well as supply chain and investment opportunities.

“This whole journey has been unbelievable. When I applied for the Discovery Entrepreneurs Medical Technology Programme last year, I knew that I was up against stiff competition from other entrepreneurs in the SA medical and healthcare space, who also have huge passion, business acumen and vision,” said Martin.

“It is enormously encouraging to know that Discovery Health recognises the value of technology in driving innovation in healthcare. The goal of the San Francisco trip was not only to open our minds, to change our perceptions and get us to realise our full potential, it was to learn as much as possible in the leading healthcare start-up community of the world, and to make us realise that we too can compete on a global scale,” concluded Martin.

For more information contact, like us on Facebook or tweet us @eHealthNewsZA.